An increasing problem in today’s society is the spiraling number of people suffering from various sleep disorders. The research results presented in this paper support the use of a novel method that employs techniques from the classification of sleep disorders for more accurate scoring. Applying this novel method will assist researchers with better analyzing subject profiles for recommending prescriptions or to alleviate sleep disorders. In biomedical research, the use of animal models is required to experimentally test the safety and efficacy of a drug in the pre-clinical stage. We have developed a novel LSTM Recurrent Neural Network to process Pharmaco-EEG Profiles of rats to automatically score their sleep–wake stages. The results indicate improvements over the current methods; for the case of combined channels, the model accuracy improved by 1% and 3% in binary or multiclass classifications, respectively, to accuracies of 93% and 82%. In the case of using a single channel, binary and multiclass LSTM models for identifying rodent sleep stages using single or multiple electrode positions for binary or multiclass problems have not been evaluated in prior literature. The results reveal that single or combined channels, and binary or multiclass classification tasks, can be applied in the automatic sleep scoring of rodents.

There is an on-going debate about medicinal use of kratom plant (Mitragyna speciosa (MS)) on whether it has beneficial or adverse effects. This study aimed to examine long-term weight-reducing effects, toxicity, and dopamine pathway activation of MS alkaloid extract on adult male Wistar rats. In anorexic study, the rats were divided into 3 groups (n = 10), receiving intragastric administration once a day for 19 weeks as control (distilled water), chronic (20 mg/kg MS alkaloid extract) and withdrawal (20 mg/kg MS alkaloid extract for week 1-12 and distilled water for week 13-19) groups. Body weights were measured daily, and blood samples were collected at the end of study for biochemical and hematological tests. In immunohistochemistry, the effects of the extract (40 and 80 mg/kg) on the nucleus accumbens (NAc) and striatum (STr) were determined by using Fos-like immunoreactivity. From week 2 to 19, the results showed a significant reduction in body weight gain produced by the extract. Cessation of the treatment at week 12 did not result in a rebound weight gain. Chronic MS alkaloid extract treatment significantly decreased non-fasting blood sugar, triglyceride, uric acid and blood urea nitrogen (BUN). However, elevated SGOT may suggest possible hepatotoxicity. Chronic MSalkaloid extract treatment also produced baseline levels for most of the hematological parameters except a decrease of monocyte. In immunohistochemistry, the acute treatment did not induce Fos-like immunoreactivity in the NAc and STr.These data demonstrated the beneficial effects of the MS alkaloid extract for possible treatment of metabolic syndromes without toxicity and rewarding effect.